A Six-Person THC Study Found Pharmacokinetic Changes That Did Not Account for Observed Tolerance

A 1980 human study found changes in THC disposition during repeated oral administration, yet concluded that those changes could not account for the observed cardiovascular, psychological and skin-temperature tolerance. Detecting a pharmacokinetic change is different from demonstrating that it explains adaptation.

The challenge measured parent drug in plasma

Six subjects received repeated oral THC, with intravenous labeled THC challenges before and after that regimen. Pharmacokinetic evaluation used unchanged THC in plasma. This design separates the repeated exposure from the route used to characterize disposition.

Some parameters changed and others did not

Average clearance and an initial apparent distribution volume increased, while steady-state distribution volume and many model-dependent measures were unchanged. The pattern did not support treating every aspect of disposition as uniformly faster or larger after tolerance developed.

Urine represented only one elimination component

The fraction excreted in urine decreased, while total urine-plus-fecal elimination was not significantly changed. Total-metabolite observations also remained different from a selective parent-THC measurement. A change in one excretion pathway should not be labeled a change in total elimination without that comparison.

Interpreting the evidence

This small historical experiment illustrates the need to distinguish association from explanatory sufficiency. Its regimen and modeling cannot supply an individual's clearance rate or impairment timeline, and the authors' conclusion does not establish that pharmacokinetics never contributes to tolerance under other conditions.

Related reading: interpreting cannabis tolerance claims.

Research reference

Hunt CA; Jones RT (1980). Tolerance and disposition of tetrahydrocannabinol in man. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us